Sutent — United Healthcare
myeloid/lymphoid neoplasms with eosinophilia and FLT3 rearrangement
Initial criteria
- Diagnosis of lymphoid, myeloid, or mixed lineage neoplasms with eosinophilia
- AND FMS-like tyrosine kinase 3 (FLT3) rearrangement in chronic or blast phase
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Sutent therapy
Approval duration
12 months